References

  1. Fattarusso Vittorio, Ritter Otto. Vadémécum clinique: Du diagnostic au traitement-16e éd. 200 Paris. Masson. Google Scholar

  2. Programme commun des Nations Unies sur le VIH/SIDA (ONUSIDA). Rapport ONUSIDA sur l'épidémie mondiale de SIDA. New York: ONUSIDA ; 2012. Google Scholar

  3. Brooks JT, Kaplan JE, Masur H. What's new in the 2009 US guidelines for prevention and treatment of opportunistic infections amongadults and adolescents with HIV. HIV Med. 2009;17(3):109-114. PubMed | Google Scholar

  4. Jeffrey Eaton, Leigh Johnson, Joshua Salomon. HIV Treatment as Prevention: SystematicComparison of MathematicalModels of the Potential Impact of AntiretroviralTherapy on HIV Incidence in South Africa. PLoS Med. 2012; 9(7): 1123- 1198. PubMed | Google Scholar

  5. Paiardini M, Müller-Trutwin M. HIV-associatedchronic immune activation. ImmunolRev. 2013; 254(1): 78-101. PubMed | Google Scholar

  6. Bassett IV, Chetty S, Giddy J, Reddy S, Bishop K, Lu Z, Losina E, Freedberg KA, Walensky RP. Screeing for acute HIV infection in South Africa: Finding acute and chronicdisease. HIV Med. 2011;12(1):46-53. PubMed | Google Scholar

  7. Organisation Mondiale de la Santé (OMS). Améliorer l'accès aux traitements Antirétroviraux dans les pays à ressources limitées: Recommandations pour une approche de santé publique. Genève: OMS; 2002. Google Scholar

  8. Jong MD, Boer RJ, Wolf F, Foudraine NA, Boucher CA, Goudsmit J, Lange JM. 0vershoot of HIV-1 viraemiaafterearly discontinuation of antiretroviraltreatment. AIDS. 1997;11(11):79-84. PubMed | Google Scholar

  9. Nsakala G, Coppieters Y , Kayembe P , Eloko G. Determinants associated with the practice of double STI / HIV / AIDS and teenage pregnancy among adolescents in schools in Kinshasa, DR Congo. Journal of Epidemiology and Public Health. 2013; 10: 59-72. PubMed | Google Scholar

  10. KatharinaKranzer ,DarshiniGovindasamy , Nathan Ford , Victoria Johnston, Stephen Lawn D. Quantifying and addressinglossesalong the continuum of care for people living with HIV infection in sub-SaharanAfrica: asystematicreview. J Int AIDS Soc. 2012; 15(2): 17383. PubMed | Google Scholar

  11. Wilson E, Sereti I. Immune restorationafterantiretroviraltherapy: the pitfalls of hasty or incompleterepairs. ImmunolRev. 2013; 254(1): 343-354. PubMed | Google Scholar

  12. Ume Abbas, Glaubius R, Mubayi A, Hood G, Mellors J. AntiretroviralTherapy and Pre-exposureProphylaxis: Combined Impact on HIV Transmission and Drug Resistance in South Africa. J Infect Dis. 2013; 208(2): 224-234. PubMed | Google Scholar

  13. Badré-Sentenac S, Essomba C, Commeyras C, Kouanfack C, Rey JL. Utilisation du renouvellement des ordonnances d'antirétroviraux comme indicateur d'observance à Yaoundé. J Pharm Clin. 2005;24(4):225-31. PubMed | Google Scholar

  14. Orrell C, Wood R. Initial data on antiretroviraladherence in Cape Town, South Africa. IAS Conf HIV PathogTreat. 2001; 1st: Abstract No 696. Google Scholar

  15. Lanièce I, Ciss M, Desclaux A, Diop K, Mbodj F, Ndiaye B, Sylla O, Delaporte E, Ndoye I. Adherence to HAART and its principal determinants in a cohort of Senegaleseadults. AIDS. 2003; 17(3):103-8. PubMed | Google Scholar

  16. Mbopi-Kéou F-X, Dempouo Djomassi L, Monebenimp F. Etude des facteurs liés à l'observance au traitement antirétroviral chez les patients suivis à l?Unité de Prise En Charge du VIH/SIDA de l'Hôpital de District de Dschang, Cameroun. The Pan AfricanMedical Journal. 2012;12:55. PubMed | Google Scholar

  17. Comité National de Lutte contre le SIDA du Cameroun (CNLS). Plan Stratégique de lutte contre le VIH/SIDA au Cameroun 2011-2015. Yaoundé, CNLS 2010 ; 21p. Google Scholar

  18. Essomba EN, Bita A, Lehman L. Riskbehavior of HIV transmission of pupils and students in Douala, Cameroon. Mali médical. 2013; 23(4): 56-64. PubMed | Google Scholar

  19. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drugfailure in proteaseinhibitormonotherapy. JAMA. 1996; 276(24): 1955-6. PubMed | Google Scholar

  20. Chkhartishvili N, Sharvadze L, Dvali N et al. Virologicoutcomes of second-line antiretroviraltherapy in EasternEuropean country of Georgia. AIDS Research and Therapy. 2014;11:18. PubMed | Google Scholar

  21. Bessette D, Bunguener M, Costagliola D, Flori Y, Matheron S, Morin M. L'observance aux traitements VIH/SIDA : mesure, déterminants, évolution. 2001. Paris. ARNS : P 21-32. Google Scholar

  22. Kim SH, Gerver SM, Fidler S, Ward H. Adherence to antiretroviraltherapy in adolescents living with HIV: systematicreview and meta-analysis. AIDS. 2014; 28(13): 1945-56. PubMed | Google Scholar

  23. Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP. Adherence to highly active antiretroviraltherapies (HAART) in HIV-infected patients: fromapredictive to a dynamicapproach. Soc Sci Med. 2002; 54(10): 1481-96. PubMed | Google Scholar

  24. Kra O, Aba YT, Yao KH, Ouattara B, Abouo F, Tanon KA, Eholié S, Bissagnené E. Profil clinicobiologique, thérapeutique et évolutif des patients infectés par le VIH hospitalisés au service des maladies infectieuses et tropicales d'Abidjan. Bull Soc patholexot. 2012; 106(1): 37-42. PubMed | Google Scholar

  25. Siu GE, Wight D, Seeley J. Dented and 'resuscitatedmasculinities: the impact of HIV diagnosis and/or enrolment on antiretroviraltreatment on masculine identities in rural eastern Uganda. Sahara J. 2014; 11(1): 211-21. PubMed | Google Scholar

  26. Folefack Tengomo G. Les déterminants de la non observance à la thérapie antirétrovirale par les patients adultes infectés par le VIH et suivis au CHU de Cotonou. IRSP. 2003; 4(8) : 112- 146. PubMed | Google Scholar

  27. Comité National de Lutte contre le SIDA (CNLS). Rapport annuel 2011 des activités de lutte contre le VIH, SIDA et les IST au Cameroun. Yaoundé: CNLS, 2012. Google Scholar

  28. Oumar AA, Dao S, Diamoutene A, Coulibaly S, Koumare B, Maiga II, Mariko E. Factors associated with antiretroviral treatment observance at Point “G”hospital. Mali Med. 2007; 22(1):18-21. PubMed | Google Scholar

  29. Oku AO, Owoaje ET, Ige OK, Oyo-ita A. Prevalence and determinants of adherence to HAART amongst PLHIV in a tertiaryhealthfacility in south-south Nigeria. BMC InfectiousDiseases. 2013;13(1):401. PubMed | Google Scholar

  30. Williams AB, Amico KR, Bova C, Womack JA. A proposal for quality standards for measuringmedicationadherence in research. AIDS Behav. 2013; 17(1): 284-297. PubMed | Google Scholar

  31. Sharma S, Khadga P, Dhungana GP, Chitrakar U. Medicationadherence to antiretroviral therapy among patients visiting antiretroviral therapy center at Tribhuvan University Teaching Hospital, Kathmandu Nepal. Kathmandu Univ .Med J (KUMJ). 2013;11 (41):50-3. PubMed | Google Scholar

  32. Finitsis DJ, Pellowski JA, Johnson BT. Text Message Intervention Designs to PromoteAdherence to AntiretroviralTherapy (ART): A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2014; 9(2): 88166. PubMed | Google Scholar

  33. Duran S, Solas C, Spire B, Carrieri MP, Fuzib JG, Costagliola D. Do HIV-infected injecting drug users over-report adherence to highly active antiretroviraltherapy' A comparison between patients'self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohortstudy. AIDS. SIDA. 2001; 15 (8): 1075-7. PubMed | Google Scholar

  34. Azmeraw D, Wasie B. Factors associated with adherence to highly active antiretrovira ltherapy among children in two referral hospitals, northwestEthiopia. Ethiop Med J. 2012; 50(2):115-24. PubMed | Google Scholar

  35. Emamzadeh-Fard S, Fard SE, Seyed Alinaghi S, Paydary K. Adherence to anti-retroviral therapy and its determinants in HIV/AIDS patients: areview. Infect Disord Drug Targets. 2012;12(5):346-56. PubMed | Google Scholar